New compound destroys breast cancer

Mark Randall Havens
ERX-41 has been shown to kill all types of breast cancer cells and other forms of human cancerous tumors.Photo byAngiola Harry on UnsplashonUnsplash

A newly created compound, ERX-41, has been found to kill a wide range of hard-to-treat types of cancers.

The compound was studied in healthy mice by the creator's research team and showed no adverse effects. The researchers believe that the treatment could be a major breakthrough for triple-negative breast carcinoma patients.

Researchers have also found that ERX41 is effective against other forms of human cancerous tumors, including deadly types of ovarian and pancreatic cancer. It has also been shown to work with glioblastoma, which is a deadly and fatal form of brain cancer.
A cancer cell is killed when ERX-41 (green stick figure) binds to the lysosomal acid lipase A protein.Photo byThe University of Texas at Dallas

ERX41 binds with a protein called LIPA in the endoplasmic reticulum, stressing the cancer cell and initiating its self-destruction protocol trigger that is typical of a normal cell.

Research shows that ERX41 is a stressor on the endoplasmic reticulum that kills cancer cells, but it doesn’t kill normal cells. Its creator states that the molecule behaves intelligently because it targets only tumor-relevant factors.
UT Dallas associate professor Jung-Mo Ahn has synthesized a novel compound known as ERX-41, which is showing promise for treating cancer.Photo byThe University of Texas at Dallas

Dr. Jung-Mo Ahn, creator of ERX-41, has tested it against breast-cancer cells. It is shown to kill all types of breast cancer cells, regardless of estrogen receptors. The compound also killed triple-negative breast carcinoma cells more effectively than it did ER-positive cells.

Ahn conducted his work in collaboration with Dr. Ratna Vadlamudi and Dr. TaeKyung Lee in order to study the ERX41 molecule.

Ahn's research was supported by The Welch Foundation, The Cancer Prevention and Research Institute of Texas, and the National Cancer Institute.

Ahn has patents on ERX-41 and related compounds. His company plans clinical trials to start in 2023.

EtiraRx, a startup in Dallas, is currently completing preclinical studies on ERX-41.

Comments / 6

Published by

Mark Havens is a serial entrepreneur and writer with a Master of Science in Management and a Bachelor of Science in Computer Science. He is the founder of the Dallas Maker Community, Dallas Makerspace and the Director of COPARENT. A cult and abuse survivor, Havens uses his personal journey and technical expertise to explore relationships, mind control, and healing in his writing, inspiring others to find their own voice. Recognized for his work in the maker community, Havens received a Ph.D. fellowship from the University of Texas at Arlington and resides in the Dallas-Fort Worth Metroplex with his mother and two children.

Dallas, TX

More from Mark Randall Havens

Comments / 0